Argus Research — sell-side record
Argus Research made 50 rating actions across 40 covered names in the last 12 months, 90% of them Buy-type and 0% Sell-type. Of its 24 price targets that resolved, 19 (79%) were reached while they stood, 4 were replaced by Argus Research before their deadline and 1 fell short at it. 4 of its 7 Buy- and Sell-type ratings that ran a full horizon agreed with how the stock did against its sector.
46 covered names with a call from Argus Research in the last two years, checked through 2026-10-29. Rebuilt every morning.
By name
| Ticker | Rating actions, 12 mo | Targets reached | Replaced early | Short | Resolved | Ratings vs sector |
|---|---|---|---|---|---|---|
| HOOD | 3 | 1 (50%) | 1 | 0 | 2 | — |
| AMD | 1 | 2 (100%) | 0 | 0 | 2 | 1 of 1 |
| AMGN | 3 | 1 (100%) | 0 | 0 | 1 | — |
| AAPL | 2 | 1 (100%) | 0 | 0 | 1 | — |
| AMAT | 2 | 1 (100%) | 0 | 0 | 1 | — |
| CRWD | 2 | 0 (0%) | 1 | 0 | 1 | — |
| MRK | 2 | 1 (100%) | 0 | 0 | 1 | — |
| NFLX | 2 | 0 (0%) | 1 | 0 | 1 | — |
| SPCX | 2 | 1 (100%) | 0 | 0 | 1 | — |
| COST | 1 | 0 (0%) | 1 | 0 | 1 | 0 of 1 |
| GOOGL | 1 | 1 (100%) | 0 | 0 | 1 | — |
| MDT | 1 | 0 (0%) | 0 | 1 | 1 | 0 of 1 |
| MRNA | 1 | 1 (100%) | 0 | 0 | 1 | — |
| MSFT | 1 | 1 (100%) | 0 | 0 | 1 | — |
| NET | 1 | 1 (100%) | 0 | 0 | 1 | — |
| NVDA | 1 | 1 (100%) | 0 | 0 | 1 | — |
| PLTR | 1 | 1 (100%) | 0 | 0 | 1 | — |
| UNH | 1 | 1 (100%) | 0 | 0 | 1 | — |
| USB | 1 | 1 (100%) | 0 | 0 | 1 | — |
| AVGO | 0 | 1 (100%) | 0 | 0 | 1 | 0 of 1 |
| BAC | 0 | 1 (100%) | 0 | 0 | 1 | 1 of 1 |
| LRCX | 0 | 1 (100%) | 0 | 0 | 1 | 1 of 1 |
| ABT | 1 | — | — | — | 0 | — |
| AMZN | 1 | — | — | — | 0 | — |
| BA | 1 | — | — | — | 0 | — |
| BSX | 1 | — | — | — | 0 | — |
| CEG | 1 | — | — | — | 0 | — |
| CME | 1 | — | — | — | 0 | — |
| COP | 1 | — | — | — | 0 | — |
| DIS | 1 | — | — | — | 0 | — |
| DKNG | 1 | — | — | — | 0 | — |
| FSLR | 1 | — | — | — | 0 | — |
| HAL | 1 | — | — | — | 0 | — |
| HD | 1 | — | — | — | 0 | — |
| MGM | 1 | — | — | — | 0 | — |
| ORCL | 1 | — | — | — | 0 | — |
| PANW | 1 | — | — | — | 0 | — |
| PFE | 1 | — | — | — | 0 | — |
| PNC | 1 | — | — | — | 0 | — |
| REGN | 1 | — | — | — | 0 | — |
| SCHW | 1 | — | — | — | 0 | — |
| TFC | 1 | — | — | — | 0 | — |
| WFC | 1 | — | — | — | 0 | — |
| ABBV | 0 | — | — | — | 0 | 1 of 1 |
| EOG | 0 | — | — | — | 0 | — |
| TSLA | 0 | — | — | — | 0 | — |
Per-name counts are small; no percentage on one name is a measure of skill.
Latest calls
| Date | Ticker | Rating | Action | Price at call | Target | Target status | Move in the 30 days before |
|---|---|---|---|---|---|---|---|
| 2026-10-27 | ABT | Buy → Hold | downgrade | $103.10 | — | no target | +1.8% |
| 2026-10-22 | NFLX | Buy | maintained | $67.05 | $95 | running to 2027-10-22 | -7.1% |
| 2026-10-01 | REGN | Hold → Buy | upgrade | $734.81 | $850 | running to 2027-10-01 | -10.8% |
| 2026-09-28 | COST | Buy | reiterated | $922.92 | $1230 | running to 2027-09-28 | -2.4% |
| 2026-09-14 | ORCL | Buy | reiterated | $144.79 | $225 | running to 2027-09-14 | -3.8% |
| 2026-09-03 | PANW | Buy | reiterated | $331.94 | $425 | running to 2027-09-03 | -9.4% |
| 2026-08-28 | CRWD | Buy | maintained | $218.40 | $425 | running to 2027-08-28 | +21.8% |
| 2026-08-28 | MRNA | Hold → Buy | upgrade | $137.99 | $180 | reached 2026-09-22 | +153.2% |
| 2026-08-26 | FSLR | Buy | reiterated | $205.93 | $275 | running to 2027-08-26 | +0.1% |
| 2026-08-25 | MRK | Buy | maintained | $156.45 | $170 | running to 2027-08-25 | +19.4% |
Other firms: Barclays · Wells Fargo · Morgan Stanley · UBS · Citigroup · RBC Capital · JPMorgan · Truist Securities · TD Cowen · Cantor Fitzgerald · Evercore ISI Group · Piper Sandler. All firms.
How calls are checked
Every call is checked on the firm's own terms. A price target is followed until its own deadline (12 months unless the firm publishes a different horizon) and ends as reached (the stock closed at or beyond it while it stood), replaced (the same firm set a new target first) or short at deadline. A rating is compared with the stock's sector SPDR ETF on total return over the rating's life, because most big-firm ratings are relative: Overweight means "beat its peers", not "go up". Hold-type ratings are tracked, not graded. A firm is numbered only with 30+ resolved targets, and a letter prints only for a firm's whole record where an exact test separates it from a coin flip. None of this is a verdict on anyone's skill, and one day is never a grade. The full method →
Get the daily brief
Our take, the S&P 500 Pulse, the Street's calls and today's docket — one email, weekdays, 9 AM ET, 30 minutes before the open.